Global Cancer Monoclonal Antibodies Market to Continue Growing Strongly
In the past few years, monoclonal antibodies (mAbs) have dominated the targeted cancer drug sales growth due to their unique ability to bind to specific antigens within human cells, tissues and organs. Proliferation in the number of new cancer cases and other key factors led to create a US$ 21 Billion worldwide market for antineoplastic mAbs in 2011. According to a new research report by RNCOS, the market is moving towards innovative mAbs that seek to deliver effective treatments. It...
View full press release